Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
AssigneeOsiris Therapeutics, Inc.
InventorsMark A. Thiede, Gabriel Mbalaviele
Life of this patent
Estimating the term…
Abstract
The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.
Claims14
A method for producing osteoclasts in vitro comprising co-culturing mesenchymal stem cells with hematopoietic stem cells such that the hematopoietic stem cells produce osteoclasts.
The method of claim 2 wherein co-culturing is done in the absence of exogenous cytokines.
A method of producing genetically modified osteoclasts, comprising transducing hematopoietic progenitor cells with exogenous genetic material;
- and culturing the transduced hematopoietic cells in the presence of mesenchymal stem cells to induce differentiation of the transduced hematopoietic cells into osteoclasts that contain the exogenous genetic material.
A method of obtaining genetically modified osteoclasts comprising transducing hematopoietic progenitor cells with exogenous genetic material and placing the transduced hematopoietic cells under conditions suitable for differentiation of the hematopoietic stem cells into osteoclast cells that contain the exogenous genetic material.
A composition comprising genetically modified osteoclasts.
A method for inibiting differentiation of hematopoietic stem cells into osteoclasts comprising co-culturing differentiating mesenchymal stem cells with hematopoietic stem cells such that osteoclastogenesis is inhibited.
Dependencies are inferred from the claim text.